Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Antimicrobial Remedies and Emerging Strategies for the Treatment of Diabetic Foot Ulcers

Author(s): Muzammil Husain and Yogeeta O. Agrawal*

Volume 19, Issue 5, 2023

Published on: 12 April, 2022

Article ID: e280222201513 Pages: 13

DOI: 10.2174/1573399818666220228161608

Price: $65

Abstract

Background: Diabetic foot ulcers (DFU) are one of the most serious complications in diabetic health treatment. The treatment for DFUs is more challenging, especially in individuals with a weakened immune system. Furthermore, due to developing antibiotic resistance characteristics among harmful bacteria and fungi, existing antibiotics may not be helpful in combating microbial infections in the wound site.

Objective: This review will focus on the newest advances in antimicrobial treatments, such as dressings and topical therapies, as well as drugs and debridement methods.

Methods: The English-language publications published on DFU were collected from a variety of sources, including Scopus, Web of Science, Bentham Science, Science Direct, and Google Scholar.

Results: DFU therapy necessitates a multidisciplinary strategy including the use of appropriate diagnostic instruments, expertise, and experience. This begins with patient education and the use of new classifications to direct care in order to avoid amputations. To gain a deeper understanding of the microbiota in DFUs, new diagnostic approaches, such as the 16S ribosomal DNA sequence in bacteria, should become usable.

Conclusion: DFU is said to have a polymicrobial nature and, depending on its geographical area, some distinct characteristics, such as wound characteristics, antibiograms based on local epidemiology, individualized antimicrobial driven treatment, routine debridement, regular wound examination, and dressing changes. New biological and molecular therapies that have been shown to enhance infection prevention, the management of the local inflammatory profile, and the efficiency of the cicatrizing mechanism often help with the above characteristics.

Keywords: DFUs, diabetes mellitus, debridement techniques, antimicrobial peptides, diabetic neuropathy, biofilms.

[1]
Jiménez PG, Martín-Carmona J, Hernández EL. Diabetes mellitus. Med 2020; 13(16): 883-90.
[2]
Poretsky L. Principles of Diabetes Mellitus. Switzerland: Springer Nature 2010; pp. 1-887.
[http://dx.doi.org/10.1007/978-0-387-09841-8]
[3]
Aynalem SB, Zeleke AJ. Prevalence of diabetes mellitus and its risk factors among individuals aged 15 years and above in Mizan-Aman Town, Southwest Ethiopia, 2016: A cross sectional study. Int J Endocrinol 2018; 2018: 9317987.
[http://dx.doi.org/10.1155/2018/9317987] [PMID: 29853887]
[4]
Endris T, Worede A, Asmelash D. Prevalence of diabetes mellitus, prediabetes and its associated factors in Dessie town, northeast Ethiopia: A community-based study. Diabetes. Diabetes Metab Syndr Obes 2019; 12: 2799-809.
[http://dx.doi.org/10.2147/DMSO.S225854] [PMID: 32021343]
[5]
Nugroho PS, Tianingrum NA, Sunarti S, Rachman A, Fahrurodzi DS, Amiruddin R. Predictor risk of diabetes mellitus in Indonesia, based on national health survey. Malaysian J Med Health Sci 2020; 16: 126-30.
[6]
Hussain Z, Thu HE, Shuid AN, Katas H, Hussain F. Recent advances in polymer-based wound dressings for the treatment of diabetic foot ulcer: An overview of state-of-the-art. Curr Drug Targets 2018; 19(5): 527-50.
[http://dx.doi.org/10.2174/1389450118666170704132523] [PMID: 28676002]
[7]
Moura LIF, Dias AMA, Carvalho E, de Sousa HC. Recent advances on the development of wound dressings for diabetic foot ulcer treatment-a review. Acta Biomater 2013; 9(7): 7093-114.
[http://dx.doi.org/10.1016/j.actbio.2013.03.033] [PMID: 23542233]
[8]
Li WW, Li VW. Therapeutic angiogenesis for wound healing. Wounds 2003; 15(9): 2S-12S.
[9]
Singh MR, Saraf S, Vyas A, Jain V, Singh D. Innovative approaches in wound healing: Trajectory and advances. Artif Cells Nanomed Biotechnol 2013; 41(3): 202-12.
[http://dx.doi.org/10.3109/21691401.2012.716065] [PMID: 23316788]
[10]
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293(2): 217-28.
[http://dx.doi.org/10.1001/jama.293.2.217] [PMID: 15644549]
[11]
Ruke MG, Savai J. Diabetic foot infection, biofilm & new management strategy. Diabetes Res Open Access 2019; 1(1): 7-22.
[http://dx.doi.org/10.36502/2019/droa.6152]
[12]
Yazdanpanah L, Nasiri M, Adarvishi S. Literature review on the management of diabetic foot ulcer. World J Diabetes 2015; 6(1): 37-53.
[http://dx.doi.org/10.4239/wjd.v6.i1.37] [PMID: 25685277]
[13]
Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376(24): 2367-75.
[http://dx.doi.org/10.1056/NEJMra1615439] [PMID: 28614678]
[14]
Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: A systematic review and meta-analysis †. Ann Med 2017; 49(2): 106-16.
[http://dx.doi.org/10.1080/07853890.2016.1231932] [PMID: 27585063]
[15]
Jeffcoate WJ, Vileikyte L, Boyko EJ, Armstrong DG, Boulton AJM. Current challenges and opportunities in the prevention and management of diabetic foot ulcers. Diabetes Care 2018; 41(4): 645-52.
[http://dx.doi.org/10.2337/dc17-1836] [PMID: 29559450]
[16]
Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJM. A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. Diabetes Care 2001; 24(1): 84-8.
[http://dx.doi.org/10.2337/diacare.24.1.84] [PMID: 11194247]
[17]
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94(3): 311-21.
[http://dx.doi.org/10.1016/j.diabres.2011.10.029] [PMID: 22079683]
[18]
Eldor R, Raz I, Ben Yehuda A, Boulton AJM. New and experimental approaches to treatment of diabetic foot ulcers: A comprehensive review of emerging treatment strategies. Diabet Med 2004; 21(11): 1161-73.
[http://dx.doi.org/10.1111/j.1464-5491.2004.01358.x] [PMID: 15498081]
[19]
Alavi A, Sibbald RG, Mayer D, et al. Diabetic foot ulcers: Part II. Management. J Am Acad Dermatol 2014; 70: 21.e1-21.e24.
[http://dx.doi.org/10.1016/j.jaad.2013.07.048]
[20]
McCulloch JM, Kloth L. Wound Healing: Evidence-Based Management (Contemporary Perspectives in Rehabilitation). Philadelphia, PA, USA: FA Davis Company 2010.
[21]
Muhammad Ibrahim A. Diabetic foot ulcer: Synopsis of the epidemiology and pathophysiology. Int J Diabetes Endocrinol 2018; 3(2): 23.
[http://dx.doi.org/10.11648/j.ijde.20180302.11]
[22]
Rosyid FN. Etiology, pathophysiology, diagnosis and management of diabetics’ foot ulcer. Int J Res Med Sci 2017; 5(10): 4206.
[http://dx.doi.org/10.18203/2320-6012.ijrms20174548]
[23]
Syafril S. Pathophysiology diabetic foot ulcer. IOP Conf Ser: Earth Environ Sci 2018; 125: 012161.
[http://dx.doi.org/10.1088/1755-1315/125/1/012161]
[24]
Alavi A, Sibbald RG, Mayer D, et al. Diabetic foot ulcers: Part I. Pathophysiology and prevention. J Am Acad Dermatol 2014; 70(1): 1.e1-1.e18.
[http://dx.doi.org/10.1016/j.jaad.2013.06.055] [PMID: 24355275]
[25]
Aumiller WD, Dollahite HA. Pathogenesis and management of diabetic foot ulcers. JAAPA 2015; 28(5): 28-34.
[http://dx.doi.org/10.1097/01.JAA.0000464276.44117.b1] [PMID: 25853673]
[26]
Alsanawi Y, Alismail H. Pathogenesis and management of diabetic foot ulcers. Int J Community Med Public Health 2018; 5(11): 4953.
[http://dx.doi.org/10.18203/2394-6040.ijcmph20184249]
[27]
Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician 2002; 66(9): 1655-62.
[PMID: 12449264]
[28]
Megallaa MH, Ismail AA, Zeitoun MH, Khalifa MS. Association of diabetic foot ulcers with chronic vascular diabetic complications in patients with type 2 diabetes. Diabetes Metab Syndr 2019; 13(2): 1287-92.
[http://dx.doi.org/10.1016/j.dsx.2019.01.048] [PMID: 31336479]
[29]
Esteghamati A, Aflatoonian M, Rad MV, et al. Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. Arch Cardiovasc Dis 2015; 108(8-9): 412-9.
[http://dx.doi.org/10.1016/j.acvd.2015.01.015] [PMID: 26184866]
[30]
Muthiah A, Kandasamy R, Madasamy A. A study on diabetic foot and its association with peripheral artery disease. Int Surg J 2017; 4(4): 1217.
[http://dx.doi.org/10.18203/2349-2902.isj20170937]
[31]
Schaper NC. Diabetic foot ulcer classification system for research purposes: A progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004; 20 (SUPPL. 1): S90-5.
[http://dx.doi.org/10.1002/dmrr.464]
[32]
Loesche M, Gardner SE, Kalan L, et al. Temporal stability in chronic wound microbiota is associated with poor healing. J Invest Dermatol 2017; 137(1): 237-44.
[http://dx.doi.org/10.1016/j.jid.2016.08.009] [PMID: 27566400]
[33]
Nelson EA, Backhouse MR, Bhogal MS, et al. Concordance in diabetic foot ulcer infection. BMJ Open 2013; 3(1): e002370.
[http://dx.doi.org/10.1136/bmjopen-2012-002370] [PMID: 23293263]
[34]
Nelson A, Wright-Hughes A, Backhouse MR, et al. CODIFI (Concordance in Diabetic Foot Ulcer Infection): A cross-sectional study of wound swab versus tissue sampling in infected diabetic foot ulcers in England. BMJ Open 2018; 8(1): e019437.
[http://dx.doi.org/10.1136/bmjopen-2017-019437] [PMID: 29391370]
[35]
Jouhar L, Jaafar RF, Nasreddine R, et al. Microbiological profile and antimicrobial resistance among diabetic foot infections in Lebanon. Int Wound J 2020; 17(6): 1764-73.
[http://dx.doi.org/10.1111/iwj.13465] [PMID: 32779355]
[36]
Jneid J, Lavigne JP, La Scola B, Cassir N. The diabetic foot microbiota: A review. Hum Microbiome J 2017; 5-6: 1-6.
[http://dx.doi.org/10.1016/j.humic.2017.09.002]
[37]
Pereira SG, Moura J, Carvalho E, Empadinhas N. Microbiota of chronic diabetic wounds: Ecology, impact, and potential for innovative treatment strategies. Front Microbiol 2017; 8: 1791.
[http://dx.doi.org/10.3389/fmicb.2017.01791] [PMID: 28983285]
[38]
Martínez-De Jesús FR, Ramos-De la Medina A, Remes-Troche JM, et al. Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections. Int Wound J 2007; 4(4): 353-62.
[http://dx.doi.org/10.1111/j.1742-481X.2007.00363.x] [PMID: 17953678]
[39]
Liu PY, Shi ZY, Sheu WHH. Diagnosis and treatment of diabetic foot infections. J Intern Med Taiwan 2012; 23(6): 431-41.
[40]
Miller AO, Henry M. Update in diagnosis and treatment of diabetic foot infections. Phys Med Rehabil Clin N Am 2009; 20(4): 611-25.
[http://dx.doi.org/10.1016/j.pmr.2009.06.007] [PMID: 19781502]
[41]
Murali TS, Kavitha S, Spoorthi J, et al. Characteristics of microbial drug resistance and its correlates in chronic diabetic foot ulcer infections. J Med Microbiol 2014; 63(Pt 10): 1377-85.
[http://dx.doi.org/10.1099/jmm.0.076034-0] [PMID: 25038136]
[42]
Jain SK, Barman R. Bacteriological profile of diabetic foot ulcer with special reference to drug-resistant strains in a tertiary care center in North-East India. Indian J Endocrinol Metab 2017; 21(5): 688-94.
[http://dx.doi.org/10.4103/ijem.IJEM_546_16] [PMID: 28989875]
[43]
Karmaker M, Sanyal SK, Sultana M, Hossain MA. Association of bacteria in diabetic and non-diabetic foot infection - An investigation in patients from Bangladesh. J Infect Public Health 2016; 9(3): 267-77.
[http://dx.doi.org/10.1016/j.jiph.2015.10.011] [PMID: 26617249]
[44]
Smith K, Collier A, Townsend EM, et al. One step closer to understanding the role of bacteria in diabetic foot ulcers: characterising the microbiome of ulcers. BMC Microbiol 2016; 16(1): 54.
[http://dx.doi.org/10.1186/s12866-016-0665-z] [PMID: 27005417]
[45]
Pouget C, Dunyach-Remy C, Pantel A, Schuldiner S, Sotto A, Lavigne JP. Biofilms in diabetic foot ulcers: Significance and clinical relevance. Microorganisms 2020; 8(10): 1-15.
[http://dx.doi.org/10.3390/microorganisms8101580] [PMID: 33066595]
[46]
Donlan RM. Biofilms: Microbial life on surfaces. Emerg Infect Dis 2002; 8(9): 881-90.
[http://dx.doi.org/10.3201/eid0809.020063] [PMID: 12194761]
[47]
Jain A, Gupta Y, Agrawal R, Khare P, Jain SK. Biofilms-a microbial life perspective: A critical review. Crit Rev Ther Drug Carrier Syst 2007; 24(5): 393-443.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v24.i5.10] [PMID: 18197780]
[48]
Bhinu VS. Insight into biofilm-associated microbial life. J Mol Microbiol Biotechnol 2006; 10: 15-21.
[49]
Santos R, Veiga AS, Tavares L, Castanho M, Oliveira M. Bacterial biofilms in diabetic foot ulcers: Potential alternative therapeutics. In: Dhanasekaran D, Ed. Microbial Biofilms - Importance and Applications. London: InTechOpen 2016.
[50]
Messad N, Prajsnar TK, Lina G, et al. Existence of a colonizing Staphylococcus aureus strain isolated in diabetic foot ulcers. Diabetes 2015; 64(8): 2991-5.
[http://dx.doi.org/10.2337/db15-0031] [PMID: 25901094]
[51]
Sharma D, Misba L, Khan AU. Antibiotics versus biofilm: An emerging battleground in microbial communities. Antimicrob Resist Infect Control 2019; 8: 76.
[http://dx.doi.org/10.1186/s13756-019-0533-3] [PMID: 31131107]
[52]
Srivastava P, Sivashanmugam K. Combinatorial drug therapy for controlling Pseudomonas aeruginosa and its association with chronic condition of diabetic foot ulcer. Int J Low Extrem Wounds 2020; 19(1): 7-20.
[http://dx.doi.org/10.1177/1534734619873785] [PMID: 31535600]
[53]
Johani K, Malone M, Jensen S, et al. Microscopy visualisation confirms multi-species biofilms are ubiquitous in diabetic foot ulcers. Int Wound J 2017; 14(6): 1160-9.
[http://dx.doi.org/10.1111/iwj.12777] [PMID: 28643380]
[54]
Shahi SK, Kumar A. Isolation and genetic analysis of multidrug resistant bacteria from diabetic foot ulcers. Front Microbiol 2016; 6(JAN): 1464.
[http://dx.doi.org/10.3389/fmicb.2015.01464] [PMID: 26779134]
[55]
Ji X, Jin P, Chu Y, Feng S, Wang P. Clinical characteristics and risk factors of diabetic foot ulcer with multidrug-resistant organism infection. Int J Low Extrem Wounds 2014; 13(1): 64-71.
[http://dx.doi.org/10.1177/1534734614521236] [PMID: 24520007]
[56]
Zubair M, Malik A, Ahmad J. Clinico-bacteriology and risk factors for the diabetic foot infection with multidrug resistant microorganisms in north India. Biol Med (Aligarh) 2010; 2(4): 22-34.
[57]
Xie X, Bao Y, Ni L, Liu D, Niu S, Lin H, et al. bacterial profile and antibiotic resistance in patients with diabetic foot ulcer in Guangzhou, southern china: focus on the differences among different Wagner’s grades, IDSA/IWGDF grades, and ulcer types. Int J Endocrinol 2017; 2017
[58]
Adeyemo AT, Kolawole B, Rotimi VO, Aboderin AO. Multicentre study of the burden of multidrug-resistant bacteria in the aetiology of infected diabetic foot ulcers. Afr J Lab Med 2021; 10(1): 1261.
[http://dx.doi.org/10.4102/ajlm.v10i1.1261] [PMID: 33824857]
[59]
Matta-Gutiérrez G, García-Morales E, García-Álvarez Y, Álvaro-Afonso FJ, Molines-Barroso RJ, Lázaro-Martínez JL. The influence of multidrug-resistant bacteria on clinical outcomes of diabetic foot ulcers: A systematic review. J Clin Med 2021; 10(9): 1948.
[http://dx.doi.org/10.3390/jcm10091948] [PMID: 34062775]
[60]
Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot? Diabetes Metab Res Rev 2000; 16 (SUPPL. 1).
[http://dx.doi.org/10.1002/1520-7560(200009/10)16:1+<::AIDDMRR139>3.0.CO;2-8]
[61]
Balows A. Molecular medical microbiology. Diagn Microbiol Infect Dis 2002; 43(2): 173-4.
[http://dx.doi.org/10.1016/S0732-8893(02)00377-2]
[62]
Tayeb KA. Managing infection: A holistic approach. J Wound Care 2015; 24(5) (Suppl. 2): 20-30.
[http://dx.doi.org/10.12968/jowc.2015.24.Sup5b.20] [PMID: 26079164]
[63]
Attinger C, Wolcott R. Clinically addressing biofilm in chronic wounds. Adv Wound Care (New Rochelle) 2012; 1(3): 127-32.
[http://dx.doi.org/10.1089/wound.2011.0333] [PMID: 24527292]
[64]
Kataoka Y, Kunimitsu M, Nakagami G, Koudounas S, Weller CD, Sanada H. Effectiveness of ultrasonic debridement on reduction of bacteria and biofilm in patients with chronic wounds: A scoping review. Int Wound J 2021; 18(2): 176-86.
[http://dx.doi.org/10.1111/iwj.13509] [PMID: 33236843]
[65]
Yarets Y. Effective biofilm removal and changes in bacterial biofilm building capacity after wound debridement with low-frequency ultrasound as part of wound bed preparation before skin grafting. Chronic Wound Care Manag Res 2017; 4: 55-64.
[http://dx.doi.org/10.2147/CWCMR.S127874]
[66]
Dhar Y, Han Y. Current developments in biofilm treatments: Wound and implant infections. Eng Regen 2020; 1: 64-75.
[http://dx.doi.org/10.1016/j.engreg.2020.07.003]
[67]
Wolcott R. Disrupting the biofilm matrix improves wound healing outcomes. J Wound Care 2015; 24(8): 366-71.
[http://dx.doi.org/10.12968/jowc.2015.24.8.366] [PMID: 26562379]
[68]
Dreyfus J, Delhougne G, James R, Gayle J, Waycaster C. Clostridial collagenase ointment and medicinal honey utilization for pressure ulcers in US hospitals. J Med Econ 2018; 21(4): 390-7.
[http://dx.doi.org/10.1080/13696998.2017.1423489] [PMID: 29295637]
[69]
Waycaster C, Carter MJ, Gilligan AM, Mearns ES, Fife CE, Milne CT. Comparative cost and clinical effectiveness of clostridial collagenase ointment for chronic dermal ulcers. J Comp Eff Res 2018; 7(2): 149-65.
[http://dx.doi.org/10.2217/cer-2017-0066] [PMID: 29076747]
[70]
Naomi R, Fauzi MB. Cellulose/collagen dressings for diabetic foot ulcer: A review. Vol. 12. Pharmaceutics 2020; 12(9): 1-18.
[http://dx.doi.org/10.3390/pharmaceutics12090881] [PMID: 32957476]
[71]
Zhang X, Sun D, Jiang GC. Comparative efficacy of nine different dressings in healing diabetic foot ulcer: A Bayesian network analysis. J Diabetes 2019; 11(6): 418-26.
[http://dx.doi.org/10.1111/1753-0407.12871] [PMID: 30324760]
[72]
Dumville JC, Deshpande S, O’Meara S, Speak K. Hydrocolloid dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev 2013; 2013(8): CD009099.
[http://dx.doi.org/10.1002/14651858.CD009099.pub3] [PMID: 23922167]
[73]
Kwon KT, Armstrong DG. Microbiology and antimicrobial therapy for diabetic foot infections. Infect Chemother 2018; 50(1): 11-20.
[http://dx.doi.org/10.3947/ic.2018.50.1.11] [PMID: 29637748]
[74]
Haldar J, Mukherjee P, Mukhopadhyay S, Maiti PK. Isolation of bacteria from diabetic foot ulcers with special reference to anaerobe isolation by simple two-step combustion technique in candle jar. Indian J Med Res 2017; 145(1): 97-101.
[http://dx.doi.org/10.4103/ijmr.IJMR_1436_14] [PMID: 28574021]
[75]
Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005; 366(9498): 1695-703.
[http://dx.doi.org/10.1016/S0140-6736(05)67694-5] [PMID: 16291062]
[76]
Roberts AD, Simon GL. Diabetic foot infections: The role of microbiology and antibiotic treatment. Semin Vasc Surg 2012; 25(2): 75-81.
[http://dx.doi.org/10.1053/j.semvascsurg.2012.04.010] [PMID: 22817856]
[77]
Karri VVSR, Kuppusamy G, Talluri SV, Yamjala K, Mannemala SS, Malayandi R. Current and emerging therapies in the management of diabetic foot ulcers. Curr Med Res Opin 2016; 32(3): 519-42.
[http://dx.doi.org/10.1185/03007995.2015.1128888] [PMID: 26643047]
[78]
Ahmed A, Getti G, Boateng J. Ciprofloxacin-loaded calcium alginate wafers prepared by freeze-drying technique for potential healing of chronic diabetic foot ulcers. Drug Deliv Transl Res 2018; 8(6): 1751-68.
[http://dx.doi.org/10.1007/s13346-017-0445-9] [PMID: 29134555]
[79]
Yingsakmongkol N. Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers. J Wound Care 2013; 22(3): 130-132, 134-136.
[http://dx.doi.org/10.12968/jowc.2013.22.3.130] [PMID: 23665731]
[80]
Gasca-Lozano LE, Lucano-Landeros S, Ruiz-Mercado H, et al. Pirfenidone accelerates wound healing in chronic diabetic foot ulcers: A randomized, double-blind controlled trial. J Diabetes Res 2017; 2017: 3159798.
[http://dx.doi.org/10.1155/2017/3159798] [PMID: 29675430]
[81]
Ram M, Singh V, Kumawat S, et al. Deferoxamine modulates cytokines and growth factors to accelerate cutaneous wound healing in diabetic rats. Eur J Pharmacol 2015; 764: 9-21.
[http://dx.doi.org/10.1016/j.ejphar.2015.06.029] [PMID: 26101070]
[82]
Maderal AD, Vivas AC, Eaglstein WH, Kirsner RS. The FDA and designing clinical trials for chronic cutaneous ulcers. Semin Cell Dev Biol 2012; 23(9): 993-9.
[http://dx.doi.org/10.1016/j.semcdb.2012.09.014] [PMID: 23063664]
[83]
Tecilazich F, Dinh TL, Veves A. Emerging drugs for the treatment of diabetic ulcers. Expert Opin Emerg Drugs 2013; 18(2): 207-17.
[http://dx.doi.org/10.1517/14728214.2013.802305] [PMID: 23687931]
[84]
Parizad N, Hajimohammadi K, Goli R. Surgical debridement, maggot therapy, negative pressure wound therapy, and silver foam dressing revive hope for patients with diabetic foot ulcer: A case report. Int J Surg Case Rep 2021; 82: 105931.
[http://dx.doi.org/10.1016/j.ijscr.2021.105931] [PMID: 33962267]
[85]
Maranna H, Lal P, Mishra A, et al. Negative pressure wound therapy in grade 1 and 2 diabetic foot ulcers: A randomized controlled study. Diabetes Metab Syndr 2021; 15(1): 365-71.
[http://dx.doi.org/10.1016/j.dsx.2021.01.014] [PMID: 33524646]
[86]
Finžgar M, Frangež HB, Cankar K, Frangež I. Transcutaneous application of the gaseous CO2 for improvement of the microvascular function in patients with diabetic foot ulcers. Microvasc Res 2021; 133: 104100.
[http://dx.doi.org/10.1016/j.mvr.2020.104100] [PMID: 33181169]
[87]
Fang J, Xu J, Zhang Y, et al. Stromal cell-derived factor-1 may play pivotal role in distraction-stimulated neovascularization of diabetic foot ulcer. Med Hypotheses 2021; 149: 110548.
[http://dx.doi.org/10.1016/j.mehy.2021.110548] [PMID: 33690002]
[88]
Shao S, Pan R, Chen Y. Autologous platelet-rich plasma for diabetic foot ulcer. Trends Endocrinol Metab 2020; 31(12): 885-90.
[http://dx.doi.org/10.1016/j.tem.2020.10.003] [PMID: 33199085]
[89]
Uzun E, Güney A, Gönen ZB, et al. Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: Phase I/2 safety study. Foot Ankle Surg 2021; 27(6): 636-42.
[PMID: 32826167]
[90]
He S, Liang C, Yi C, Wu M. Therapeutic effect of continuous diffusion of oxygen therapy combined with traditional moist wound dressing therapy in the treatment of diabetic foot ulcers. Diabetes Res Clin Pract 2021; 174: 108743.
[http://dx.doi.org/10.1016/j.diabres.2021.108743] [PMID: 33713718]
[91]
Terabe Y, Kaneko N, Nakabayashi K, Matsui A, Ando H. Long-term efficient management of diabetic foot ulcer using simultaneous foot ulcer closure and surgical off-loading. JPRAS Open 2021; 30: 1-5.
[http://dx.doi.org/10.1016/j.jpra.2021.04.012] [PMID: 34307819]
[92]
Srivastava P, Sivashanmugam K. Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients. Infect Genet Evol 2021; 92: 104824.
[http://dx.doi.org/10.1016/j.meegid.2021.104824] [PMID: 33774177]
[93]
Davani F, Alishahi M, Sabzi M, Khorram M, Arastehfar A, Zomorodian K. Dual drug delivery of vancomycin and imipenem/cilastatin by coaxial nanofibers for treatment of diabetic foot ulcer infections. Mater Sci Eng C 2021; 123: 111975.
[http://dx.doi.org/10.1016/j.msec.2021.111975] [PMID: 33812603]
[94]
Fadol EM, Suliman HM, Osman B, et al. Therapeutic outcomes evaluation of adjuvant hyperbaric oxygen therapy for non-healing diabetic foot ulcers among Sudanese patients. Diabetes Metab Syndr 2021; 15(4): 102173.
[http://dx.doi.org/10.1016/j.dsx.2021.06.010] [PMID: 34186354]
[95]
Yuan Y, Ding X, Jing Z, et al. Modified tibial transverse transport technique for the treatment of ischemic diabetic foot ulcer in patients with type 2 diabetes. J Orthop Translat 2021; 29: 100-5.
[http://dx.doi.org/10.1016/j.jot.2021.04.006] [PMID: 34136348]
[96]
Suresh TC, Poonguzhali TV, Anuradha V, Ramesh B, Suresh G. Aqueous extract of Turbinaria conoides (J. Agardh) kutzing mediated fabrication of silver nanoparticles used against bacteria associated with diabetic foot ulcer. Mater Today Proc 2021; 43(5): 3038-43.
[97]
Dixon D, Edmonds M. Managing diabetic foot ulcers: Pharmacotherapy for wound healing. Drugs 2021; 81(1): 29-56.
[http://dx.doi.org/10.1007/s40265-020-01415-8] [PMID: 33382445]
[98]
Alavi M, Nokhodchi A. Antimicrobial and wound treatment aspects of micro- and nanoformulations of carboxymethyl, dialdehyde, and TEMPO-oxidized derivatives of cellulose: Recent advances. Macromol Biosci 2020; 20(4): e1900362.
[http://dx.doi.org/10.1002/mabi.201900362] [PMID: 32077250]
[99]
Anwar K, Hussein D, Salih J. Antimicrobial susceptibility testing and phenotypic detection of MRSA isolated from diabetic foot infection. Int J Gen Med 2020; 13: 1349-57.
[http://dx.doi.org/10.2147/IJGM.S278574] [PMID: 33293853]
[100]
Alhubail A, Sewify M, Messenger G, et al. Microbiological profile of diabetic foot ulcers in Kuwait. PLoS One 2020; 15(12): e0244306.

Rights & Permissions Print Cite
Article Metrics
47
3
© 2024 Bentham Science Publishers | Privacy Policy